2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France

被引：20

作者：

Penault-Llorca, Frederique ^{[1
]}

Vincent-Salomon, Anne ^{[1
]}

MacGrogan, Gaetan ^{[1
]}

Roger, Pascal ^{[1
]}

Treilleux, Isabelle ^{[1
]}

Valent, Alexander ^{[1
]}

Mathieu, Marie-Christine ^{[1
]}

Antoine, Martine ^{[1
]}

Becette, Veronique ^{[1
]}

Bor, Catherine ^{[1
]}

Brabencova, Eva ^{[1
]}

Charafe-Jauffret, Emmanuelle ^{[1
]}

Chenard, Marie-Pierre ^{[1
]}

Dauplat, Marie-Melanie ^{[1
]}

Delree, Paul ^{[1
]}

Devouassoux, Mojgan ^{[1
]}

Fiche, Maryse ^{[1
]}

Fondrevelle, Marie-Eve ^{[1
]}

Fridman, Viviana ^{[1
]}

Garbar, Christian ^{[1
]}

Genin, Pascal ^{[1
]}

Ghnassia, Jean-Pierre ^{[1
]}

Haudebourg, Juliette ^{[1
]}

Laberge-Le Couteulx, Sophie ^{[1
]}

Loussouarn, Delphine ^{[1
]}

Maran-Gonzalez, Aurelie ^{[1
]}

Marcy, Myriam ^{[1
]}

Michenet, Patrick ^{[1
]}

Poulet, Bruno ^{[1
]}

Sagan, Christine ^{[1
]}

Trassard, Martine ^{[1
]}

Verriele, Veronique ^{[1
]}

Arnould, Laurent ^{[1
]}

Lacroix-Triki, Magali ^{[1
]}

机构：

[1] Unicancer, Grp Etud Facteurs Pronost Immunohistochim Canc Se, F-75654 Paris 13, France

来源：

ANNALES DE PATHOLOGIE | 2014年 / 34卷 / 05期

关键词：

HER2; Breast cancer; Immunohistochemistry; In situ hybridization; Guidelines; IN-SITU HYBRIDIZATION; CORE-NEEDLE BIOPSIES; GENE AMPLIFICATION; IMMUNOHISTOCHEMISTRY; FISH;

D O I：

10.1016/j.annpat.2014.08.018

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

International guidelines on HER2 determination in breast cancer have just been updated by the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP), on the basis of more than ten-year practice, results of clinical trials and concordance studies. The GEFPICS group, composed of expert pathologists in breast cancer, herein presents these recommendations, adapted to the French routine practice. These guidelines highlight the possible diagnosis difficulties with regards to HER2 status determination, such as intra-tumor heterogeneity, special histological subtypes and biomarker re-evaluation during metastatic relapse. Pre-analytical issues and updated scoring criteria (especially for equivocal cases) are detailed, in order to decrease the occurrence of false negative cases. In the era of personalized medicine, pathologists are more than ever involved in the quality of oncotheranostic biomarker evaluation. (C) 2014 Elsevier Masson SAS. All rights reserved.

引用

页码：352 / 365

页数：14

共 50 条

[31] The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
Avisek Majumder
Manbir Sandhu
Debarko Banerji
Veronica Steri
Adam Olshen
Mark M. Moasser
[J]. Scientific Reports, 11
[32] BORDERLINE HER2 PROTEIN POSITIVE BREAST CANCERS HAVE SIMILAR PATIENT OUTCOME REGARDLESS OF HER2 GENE AMPLIFICATION STATUS
Barros, F. F. T.
Aleskandarany, M.
Rakha, E.
Watts, S. L.
Powe, D. G.
Ellis, I. O.
Green, A. R.
[J]. EJC SUPPLEMENTS, 2010, 8 (06): : 6 - 7
[33] The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
Majumder, Avisek
Sandhu, Manbir
Banerji, Debarko
Steri, Veronica
Olshen, Adam
Moasser, Mark M.
[J]. SCIENTIFIC REPORTS, 2021, 11 (01) : 9091
[34] Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Fehm, Tanja
Becker, Sven
Duerr-Stoerzer, Silke
Sotlar, Karl
Mueller, Volkmar
Wallwiener, Diethelm
Lane, Nancy
Solomayer, Erich
Uhr, Jonathan
[J]. BREAST CANCER RESEARCH, 2007, 9 (05) : R74
[35] Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Tanja Fehm
Sven Becker
Silke Duerr-Stoerzer
Karl Sotlar
Volkmar Mueller
Diethelm Wallwiener
Nancy Lane
Erich Solomayer
Jonathan Uhr
[J]. Breast Cancer Research, 9
[36] Activating HER2 mutations in HER2 gene amplification negative breast cancers.
Bose, R.
Kavuri, S. M.
Searleman, A. C.
Shen, W.
Shen, D.
Koboldt, D. C.
Monsey, J.
Li, S.
Ding, L.
Mardis, E. R.
Ellis, M. J.
[J]. CANCER RESEARCH, 2012, 72
[37] Targeting HER2 heterogeneity in breast and gastrointestinal cancers
Valenza, Carmine
Guidi, Lorenzo
Battaiotto, Elena
Trapani, Dario
Bianchi, Andrea Sartore
Siena, Salvatore
Curigliano, Giuseppe
[J]. TRENDS IN CANCER, 2024, 10 (02): : 113 - 123
[38] Genetic heterogeneity for Her2 accounts for a significant percentage of breast cancers changing Her2 status following implementation of the 2013 CAP/ASCO HER2 reporting guidelines
Estrada, Monica V.
Giltnane, Jena M.
Wheeler, Ferrin C.
Yenamandra, Ashwini
Abramson, Vandana
Mayer, Ingrid A.
Means, Julie
Rexer, Brent
Meszoely, Ingrid M.
Sanders, Melinda E.
[J]. CANCER RESEARCH, 2015, 75
[39] Resolving the ERBB2 (HER2) Status of Invasive Breast Cancers with Double-Equivocal HER2 Status by Immunohistochemistry and Fluorescence In-situ Hybridization
Hon, Jane Date
Zhang, Xinmin
Edmonston, Tina Bocker
[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 146 : S96 - S96
[40] HER2 status in bilateral breast cancer
Crowe, Joseph P.
Patrick, Rebecca J.
Rybicki, Lisa A.
Budd, G. Thomas
Escobar, Pedro F.
Tubbs, Raymond R.
Hicks, David G.
[J]. INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2006, 51 (05) : 219 - 223

← 1 2 3 4 5 →